Key HighlightsShares of NVO advanced 6.55% during trading on June 22, 2026Britain’s regulatory body greenlit a pill-based version of Wegovy — marking the UK’s first oral GLP-1 medication for weight managementThe Novo Nordisk Foundation unveiled CardioMetabolic Bridge, a comprehensive European research program targeting obesity and diabetesBerenberg’s Kerry Holford boosted the stock’s price target to DKK 325 from DKK 300 while reaffirming a Buy recommendationChallenges persist, including mounting debt levels and significant dependence on GLP-1 medications in American marketsShares of Novo Nordisk (NVO) experienced a significant 6.55% uptick on June 22 following the simultaneous announcement of two favorable developments that reignited investor enthusiasm for the pharmaceutical giant’s obesity treatment portfolio.Novo Nordisk A/S, NVOThe advance came during a challenging year for the stock — NVO remains down approximately 12.90% year-to-date in 2026 — making Sunday’s rally particularly noteworthy.The primary driver behind the surge was Britain’s authorization of a tablet formulation of Wegovy. The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) granted approval on June 11, establishing this as the nation’s inaugural oral GLP-1 receptor agonist cleared for weight control purposes.The medication received authorization for use alongside dietary restrictions and physical activity in adults experiencing obesity or being overweight with at least one weight-related comorbidity. Clinical evidence from the Phase 3 OASIS 4 study supported the regulatory decision.Previously, British patients required injectable formulations of Wegovy. An oral alternative could expand accessibility among individuals hesitant about self-administered injections, potentially boosting prescription demand in the coming months.European Research Initiative Strengthens Market SentimentThe secondary catalyst emerged from the CardioMetabolic Bridge announcement, an expansive pan-European scientific endeavor supported financially by the Novo Nordisk Foundation. This program aims to accelerate therapeutic innovation for obesity and type 2 diabetes management.While the foundation operates independently from the pharmaceutical company, its launch demonstrates sustained institutional commitment to advancing research in Novo Nordisk’s primary therapeutic areas.Collectively, these announcements strengthened the narrative that Novo Nordisk continues advancing its competitive positioning in a rapidly evolving marketplace.From an analyst perspective, Berenberg’s Kerry Holford elevated NVO’s price objective to DKK 325 from DKK 300 on June 17, maintaining a Buy stance on the shares.The company’s market capitalization currently stands at $199.8 billion. Daily trading volume averages approximately 15.4 million shares.Lingering Concerns Remain PresentDespite positive developments, the optimistic news doesn’t eliminate the headwinds that have pressured NVO throughout 2026.The pharmaceutical firm faces an expanding balance sheet liability. Diminished cash flow generation increases vulnerability should borrowing costs remain high.Concentration risk represents another concern. A substantial proportion of Novo Nordisk’s revenue derives from GLP-1 and obesity medications, especially within American markets. Reimbursement pressures, modifications to insurance policies, or accelerated competitive advances could introduce earnings unpredictability.Technical indicators currently assign NVO a Sell signal, indicating technical analysts haven’t adopted a bullish outlook despite the recent session’s performance.Short interest comprises merely 0.51% of outstanding shares, indicating minimal short positioning that might fuel additional upward momentum.As trading concluded on June 22, NVO had advanced 6.55% for the session, with the UK oral Wegovy authorization and CardioMetabolic Bridge program identified as the key catalysts behind the movement.The post Novo Nordisk (NVO) Stock Surges 6.55% on Oral Wegovy UK Approval appeared first on Blockonomi.